MedTrace Logo

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

NCT06633042 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-11-12

No results posted yet for this study

Summary

This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory NMOSD.

Conditions

Interventions

DRUG

Universal BCMA-CD19 CART

1.0-4.0×10\^6 CAR-T cells/kg

Sponsors & Collaborators

  • Wenzhou Medical University Affiliated Ophthalmology Hospital

    collaborator UNKNOWN

  • Bioray Laboratories

    lead INDUSTRY

Principal Investigators

  • Xiaohui Wang, PhD · Wenzhou Medical University Affiliated Ophthalmology Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-25
Primary Completion
2025-10-12
Completion
2025-12-12

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06633042 on ClinicalTrials.gov